Synthesis of novel 5-(2,5-bis(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazole-2-thiol derivatives as potential glucosidase inhibitors
- PMID: 34126575
- DOI: 10.1016/j.bioorg.2021.105046
Synthesis of novel 5-(2,5-bis(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazole-2-thiol derivatives as potential glucosidase inhibitors
Abstract
Background: A hybrid molecule of different biologically active substances can improve affinity and efficiency compared to a standard drug. Hence based on this fact, we predict that a combination of fluorine, oxadiazole, sulfur, etc., may enhance α-glucosidase inhibition activity compared to a standard drug.
Methods: A series of novel 5-(2,5-bis(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazole-2-thiol derivatives (2a-2i) were synthesized and characterized using spectroscopic techniques such as 1HNMR and LC-MS. In order to evaluate its bioactivity, in vitro α-amylase and α-glycosidase inhibitory activity were performed. In vivo study was carried using a genetic model, Drosophila melanogaster, for assessing the antihyperglycemic effects.
Results: The compounds 2a-2i demonstrated α-amylase inhibitory activity in the range of IC50 = 40.00-80.00 μg/ml as compare to standard acarbose (IC50 = 34.71 μg/ml). Compounds 2a-2i demonstrated α-glucosidase inhibitory activity in the range of IC50 = 46.01-81.65 μg/ml as compared to standard acarbose (IC50 = 34.72 μg/ml). Docking studies on a target protein, N-terminal subunit of human Maltase-glucoamylase (PDB:2QMJ) was carried and the compounds were found to dock into the active site of the enzyme (Fig. 1). The predicted binding energies of the compounds were calculated. The in vitro studies indicate that compounds 2b and 2g had better activity among the synthesized compounds. Whereas in vivo study indicates that 2b, 2g, and 2i could lower glucose levels in the Drosophila, but then 17-30% reduced capacity than acarbose and may be overcome by adjusting their dosage.
Conclusions: The in vitro and in vivo studies indicate that compounds 2b and 2g had better activity among the synthesized compounds. This study has recognized that compounds like 2b, 2g, and 2i may be considered potential candidates for further developing a novel class of antidiabetic agents.
Keywords: 1,3,4-Oxadiazole; Antidiabetic agent; Antioxidant; Molecular docking; α-Amylase; α-Glucosidase.
Copyright © 2021 Elsevier Inc. All rights reserved.
Similar articles
-
New benzimidazole-oxadiazole derivatives: Synthesis, α-glucosidase, α-amylase activity, and molecular modeling studies as potential antidiabetic agents.Arch Pharm (Weinheim). 2023 May;356(5):e2200663. doi: 10.1002/ardp.202200663. Epub 2023 Feb 9. Arch Pharm (Weinheim). 2023. PMID: 36760015
-
Alpha-amylase as molecular target for treatment of diabetes mellitus: A comprehensive review.Chem Biol Drug Des. 2021 Oct;98(4):539-560. doi: 10.1111/cbdd.13909. Epub 2021 Jul 4. Chem Biol Drug Des. 2021. PMID: 34173346 Review.
-
Synthesis, In vitro α-Glucosidase Inhibitory Potential and Molecular Docking Studies of 2-Amino-1,3,4-Oxadiazole Derivatives.Med Chem. 2020;16(6):724-734. doi: 10.2174/1573406415666190612150447. Med Chem. 2020. PMID: 31195948
-
Synthetic heterocyclic candidates as promising α-glucosidase inhibitors: An overview.Eur J Med Chem. 2019 Aug 15;176:343-377. doi: 10.1016/j.ejmech.2019.04.025. Epub 2019 Apr 30. Eur J Med Chem. 2019. PMID: 31112894 Review.
-
A new entry into the portfolio of α-glucosidase inhibitors as potent therapeutics for type 2 diabetes: Design, bioevaluation and one-pot multi-component synthesis of diamine-bridged coumarinyl oxadiazole conjugates.Bioorg Chem. 2018 Apr;77:190-202. doi: 10.1016/j.bioorg.2017.12.022. Epub 2018 Jan 16. Bioorg Chem. 2018. PMID: 29421697
Cited by
-
The Synthesis, In Vitro Bio-Evaluation, and In Silico Molecular Docking Studies of Pyrazoline-Thiazole Hybrid Analogues as Promising Anti-α-Glucosidase and Anti-Urease Agents.Pharmaceuticals (Basel). 2023 Nov 25;16(12):1650. doi: 10.3390/ph16121650. Pharmaceuticals (Basel). 2023. PMID: 38139777 Free PMC article.
-
Exploring Probenecid Derived 1,3,4-Oxadiazole-Phthalimide Hybrid as α-Amylase Inhibitor: Synthesis, Structural Investigation, and Molecular Modeling.Pharmaceuticals (Basel). 2023 Mar 10;16(3):424. doi: 10.3390/ph16030424. Pharmaceuticals (Basel). 2023. PMID: 36986525 Free PMC article.
-
Novel hybrids of thiazolidinedione-1,3,4-oxadiazole derivatives: synthesis, molecular docking, MD simulations, ADMET study, in vitro, and in vivo anti-diabetic assessment.RSC Adv. 2023 Jan 9;13(3):1567-1579. doi: 10.1039/d2ra07247e. eCollection 2023 Jan 6. RSC Adv. 2023. PMID: 36712616 Free PMC article.
-
Synthesis and Evaluation of Novel S-alkyl Phthalimide- and S-benzyl-oxadiazole-quinoline Hybrids as Inhibitors of Monoamine Oxidase and Acetylcholinesterase.Pharmaceuticals (Basel). 2022 Dec 22;16(1):11. doi: 10.3390/ph16010011. Pharmaceuticals (Basel). 2022. PMID: 36678507 Free PMC article.
-
2,5-Bis(2,2,2-trifluoroethoxy)phenyl-tethered 1,3,4-Oxadiazoles Derivatives: Synthesis, In Silico Studies, and Biological Assessment as Potential Candidates for Anti-Cancer and Anti-Diabetic Agent.Molecules. 2022 Dec 8;27(24):8694. doi: 10.3390/molecules27248694. Molecules. 2022. PMID: 36557829 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous